Product Availability: In Stock (FedEx delivery within 2 business days).
Ordering: To place an order please use Add to Cart button (account not required).
Transfection Reagent for ZR-75 Cells (Breast Carcinoma Cells, CRL-1500)
- Proprietary cationic lipids formulation
High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, and pDNA
A proven reagent for establishing stable cell lines
Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
Download in vitro ZR 751 transfection protocol: [PDF]
- Download ZR751 CRISPR/Cas9 transfection protocol: [PDF]
Download PowerPoint presentation for ZR-75-1 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 93% transfection efficiency of siRNA delivery. Transfection efficiency was determined by RT-PCR
Transfection Protocol and MSDS:
Download Altogen Biosystems ZR 751 Transfection Protocol: [PDF]
Download MSDS: [PDF]
ZR-75-1 Cell Line:
The ZR-75-1 cell line is a human breast cancer cell line that was derived from a metastatic site of a patient with infiltrating ductal carcinoma in 1975. ZR-75-1 cells are commonly used in cancer research to study the biology of breast cancer and test novel therapies. Breast cancer is considered the most prevalent malignancy in females and the fifth most common cause of cancer-related fatalities among women worldwide, representing a significant public health challenge. Metastatic breast cancer is the primary cause of death in patients diagnosed with breast cancer. Preclinical cell line models could help in discovering innovative treatment options for those affected. The ZR-75 cell line is established from a 63-year-old Caucasian female with ductal carcinoma of the breast. This cell line expresses an estrogen receptor and possesses a hypertriploid chromosome number (polyploidy). In addition to producing high levels of MUC-1 mucin mRNA, the ZR-75-1 cell line has a population doubling time of nearly 80 hours. ZR-75 is an epithelial cell line and is useful for studying the properties of tumors in breast cancer patients. Altogen Biosystems offers highly efficient pre-optimized transfection kits for the ZR-75-1 cell line.
Cell line mutations:
Figure 1. Cyclophilin B silencing efficiency was determined by RT-PCR in the ZR75 cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=6).
Figure 2. Protein expression of Cyclophilin B in ZR-75-1 cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into ZR-75-1 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides preoptimized transfection kits and electroporation products for life science research. Transfection products are developed for individual cancer cell line and transfection protocols are optimized to enable high transfection efficiency of biomolecules. Altogen Biosystems developed in vivo delivery products for small animal research, mouse and rat targeted tissue delivery: liver targeted, pancreas targeted, kidney targeted, PEG-Liposome-, Nanoparticle-, Lipid-, and Polymer-based in vivo transfection kits. Advanced formulation of reagents and optimized transfection protocols provide efficient cellular delivery of charged molecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs CRO Services:
Altogen Labs provides good laboratory practice (GLP) compliant preclinical research services for IND applications and drug development. Our biology CRO services includes both efficacy studies (over 90 in-house validated xenograft models) and safety pharmacology/toxicology studies (for more details please visit AltogenLabs.com).
- 0.5 ml (Catalog #6930)
- 1.5 ml (Catalog #6931)
- 1.5 ml CRISPR (Catalog #2203)
- 8.0 ml (Catalog #7094)